Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CVRx (CVRX) EPS (Weighted Average and Diluted) (2021 - 2026)

CVRx's quarterly EPS (Weighted Average and Diluted) came in at -$0.5 in Q1 2026, up 5.66% year-on-year from -$0.47 in Q1 2025, and down 11.11% quarter-over-quarter from -$0.45 in Q4 2025.

CVRx has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.5 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 5.66% year-over-year to -$0.5; the trailing twelve-month figure through Mar 2026 stood at -$2.01 (up 6.51% YoY), and the FY2025 full-year result was -$2.04, up 23.02% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.5, down from -$0.45 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.4 in Q4 2024, with the low at -$1.04 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.54, with a median of -$0.51 recorded in 2022.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 98.89% in 2022, while the deepest fall reached 202.0% in 2022.
  • Tracing CVRX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.51 in 2022, then climbed by 13.73% to -$0.44 in 2023, then advanced by 9.09% to -$0.4 in 2024, then dropped by 12.5% to -$0.45 in 2025, then retreated by 11.11% to -$0.5 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$0.5 (Q1 2026), -$0.45 (Q4 2025), and -$0.49 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.61
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.93
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.89
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.90
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.66
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 0.51
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.85
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 2.24
10 CVRx 144.43 Mn 72.13 Mn 12.88 Mn -0.50

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.50
Dec 31, 2025 -0.45
Sep 30, 2025 -0.49
Jun 30, 2025 -0.57
Mar 31, 2025 -0.53
Dec 31, 2024 -0.40
Sep 30, 2024 -0.57
Jun 30, 2024 -0.65
Mar 31, 2024 -1.04
Dec 31, 2023 -0.44
Sep 30, 2023 -0.43
Jun 30, 2023 -0.56
Mar 31, 2023 -0.55
Dec 31, 2022 -0.51
Sep 30, 2022 -0.48
Jun 30, 2022 -0.54
Mar 31, 2022 -0.49
Dec 31, 2021 0.50
Sep 30, 2021 -0.30
Jun 30, 2021 -48.48
Mar 31, 2021 -23.92